Gilead Sciences, Inc

10-K

Quantli Newsdesk

· 4 months ago

Gilead delivered 2% revenue growth to $29.4 billion driven by 6% HIV product sales expansion, while net income surged to $8.5 billion from $480 million primarily due to non-recurring charges in 2024 including a $3.8 billion CymaBay acquisition expense and $4.2 billion in IPR&D impairment charges that did not repeat.